Hyperhomocysteinemia ‐ A risk factor for abruptio placentae

Owen, Elizabeth; Human, L.; Carolissen, A. A.; Harley, Eric H.; Odendaal, H. J.

doi:10.1023/a:1005373810756

Cited by 31 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies ( n = 922) evaluated the association between thrombophilia and placental abruption (Goddijn‐Wessel et al , 1996; Owen et al , 1997; Wiener‐Megnagi et al , 1998; Kupferminc et al , 1999, 2000a; Alfirevic et al , 2001; Agorastos et al , 2002). Overall, thrombophilia was associated with an increased risk of placental abruption, but significant associations were only observed with heterozygous factor V Leiden (OR 4·70; 95% CI 1·13–19·59) and heterozygous prothrombin (OR 7·71; 95% CI 3·01–19·76) (Fig 8).…”

Section: Resultsmentioning

confidence: 99%

Thrombophilia in pregnancy: a systematic review

et al. 2005

View full text Add to dashboard Cite

Summary Growing evidence suggests that thrombophilia is associated with venous thromboembolism (VTE) and adverse pregnancy outcomes. However, methodological limitations have made it difficult to obtain a clear overview of the overall risks. We conducted a systematic review to determine the risk of VTE and adverse pregnancy outcomes associated with thrombophilia in pregnancy. The effectiveness of prophylactic interventions during pregnancy was also evaluated. Major electronic databases were searched, relevant data abstracted and study quality assessed by two independent reviewers. Odds ratios (ORs) stratified by thrombophilia type were calculated for each outcome. A total of 79 studies were included in our review. The risks for individual thrombophilic defects were determined for VTE (ORs, 0·74–34·40); early pregnancy loss (ORs, 1·40–6·25); late pregnancy loss (ORs, 1·31–20·09); pre‐eclampsia (ORs, 1·37–3·49); placental abruption (ORs, 1·42–7·71) and intrauterine growth restriction (ORs, 1·24–2·92). Low‐dose aspirin plus heparin was the most effective in preventing pregnancy loss in thrombophilic women (OR, 1·62). Our findings confirm that women with thrombophilia are at risk of developing VTE and complications in pregnancy. However, despite the increase in relative risk, the absolute risk of VTE and adverse outcomes remains low. There is also a lack of controlled trials of antithrombotic intervention to prevent pregnancy complications. Thus, at present, universal screening for thrombophilia in pregnancy cannot be justified clinically.

show abstract

Section: Resultsmentioning

confidence: 99%

Thrombophilia in pregnancy: a systematic review

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Pregnant women with high prepregnant BMI have also been shown to have elevated levels of fibrinogen, homocysteine, and other hemostatic factors (de Vries et al 1997; Owen et al 1997; Rajkovic et al 1997; Girling and de Swiet 1998), as well as hemodynamic changes (Tomoda et al 1996) that promote coagulation, and may make the fetal brain more susceptible to infarction. Some studies have reported elevated homocysteine levels in adults with schizophrenia compared with unaffected persons (Arinami et al 1997; Susser et al 1998).…”

Section: Discussionmentioning

confidence: 99%

Maternal Prepregnant Body Mass and Risk of Schizophrenia in Adult Offspring

Schaefer

Brown

Wyatt

et al. 2000

Schizophrenia Bulletin

View full text Add to dashboard Cite

This study examined the relation between maternal prepregnant body mass index (BMI) and development of schizophrenia and schizophrenia spectrum disorders in adult offspring from the Prenatal Determinants of Schizophrenia Study. The study drew on a previously studied cohort of births occurring between 1959 and 1967 to women enrolled in a prepaid health plan. Computerized treatment registries were used to identify possible cases of schizophrenia and spectrum disorders in adult offspring belonging to the health plan from 1981 to 1997. Diagnostic interviews and medical record reviews resulted in diagnosis of 63 cases of schizophrenia and spectrum disorders; these cases and 6,570 unrelated and unaffected cohort members whose mothers also had prepregnancy measures of BMI comprised the sample for analyses. High (> or = 30.0), compared with average (20.0-26.9), maternal prepregnant BMI (kg/m2) was significantly associated with schizophrenia and spectrum disorders in the adult offspring (relative risk [RR] = 2.9; 95% confidence interval [CI] 1.3-6.6), independently of maternal age, parity, race, education, or cigarette smoking during pregnancy. Low (< or = 19.9) maternal BMI was not associated with schizophrenia and spectrum disorders (RR = 1.2; 95% CI 0.64-2.2). Future studies of this cohort will examine factors that may help explain the relationship of high maternal prepregnant BMI with schizophrenia, including nutritional and metabolic factors, toxic exposures, and obstetrical complications.

show abstract

“…Circulating levels of tHcy are reduced by approximately 36% of nonpregnant values by midnormal pregnancy 19 and return to nonpregnant levels towards the end of the last trimester in the absence of folic acid supplementation 20 . Elevated tHcy has been associated with pregnancy complications affecting both maternal health and pregnancy outcome, e.g., preeclampsia, 21 placental abruption, 22 preterm delivery, 23 NTDs, 24 congenital heart defects, 25 Down syndrome, 26 and intrauterine growth retardation 27 . Both elevated tHcy 28 and low folate status 29 have been associated with recurrent miscarriage.…”

Section: Pregnancymentioning

confidence: 99%